Hidejiro Torigoe

681 total citations
28 papers, 450 citations indexed

About

Hidejiro Torigoe is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Hidejiro Torigoe has authored 28 papers receiving a total of 450 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Hidejiro Torigoe's work include Lung Cancer Treatments and Mutations (13 papers), HER2/EGFR in Cancer Research (7 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Hidejiro Torigoe is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), HER2/EGFR in Cancer Research (7 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Hidejiro Torigoe collaborates with scholars based in Japan and United States. Hidejiro Torigoe's co-authors include Shinichi Toyooka, Junichi Soh, Kazuhiko Shien, Shuta Tomida, Hiromasa Yamamoto, Hiroki Sato, Kei Namba, Takahiro Yoshioka, Ken Suzawa and Kazunori Tsukuda and has published in prestigious journals such as PLoS ONE, Cancer Research and Scientific Reports.

In The Last Decade

Hidejiro Torigoe

24 papers receiving 449 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hidejiro Torigoe Japan 13 242 216 186 108 37 28 450
Jiyeon Yun South Korea 11 258 1.1× 256 1.2× 228 1.2× 95 0.9× 22 0.6× 19 500
Matthew R. Strickland United States 8 251 1.0× 218 1.0× 150 0.8× 74 0.7× 39 1.1× 18 475
Yaning He China 10 208 0.9× 214 1.0× 82 0.4× 153 1.4× 32 0.9× 16 423
Trine Lindsted United States 7 208 0.9× 254 1.2× 158 0.8× 91 0.8× 52 1.4× 10 439
Rebecca Watters United States 12 232 1.0× 217 1.0× 211 1.1× 139 1.3× 38 1.0× 25 519
Nirit Yarom Israel 11 269 1.1× 145 0.7× 118 0.6× 168 1.6× 32 0.9× 23 463
Shuiping Gao China 13 263 1.1× 229 1.1× 99 0.5× 194 1.8× 27 0.7× 28 539
Hoa Q. Trummell United States 13 305 1.3× 360 1.7× 176 0.9× 94 0.9× 37 1.0× 19 620
Rebecca Pharaon United States 10 181 0.7× 210 1.0× 166 0.9× 82 0.8× 32 0.9× 27 408
Shinsuke Hashida Japan 12 382 1.6× 332 1.5× 345 1.9× 225 2.1× 56 1.5× 30 719

Countries citing papers authored by Hidejiro Torigoe

Since Specialization
Citations

This map shows the geographic impact of Hidejiro Torigoe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hidejiro Torigoe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hidejiro Torigoe more than expected).

Fields of papers citing papers by Hidejiro Torigoe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hidejiro Torigoe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hidejiro Torigoe. The network helps show where Hidejiro Torigoe may publish in the future.

Co-authorship network of co-authors of Hidejiro Torigoe

This figure shows the co-authorship network connecting the top 25 collaborators of Hidejiro Torigoe. A scholar is included among the top collaborators of Hidejiro Torigoe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hidejiro Torigoe. Hidejiro Torigoe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yoshioka, Takahiro, Kazuhiko Shien, Yuta Takahashi, et al.. (2019). Acquired resistance mechanisms to afatinib in HER2‐amplified gastric cancer cells. Cancer Science. 110(8). 2549–2557. 30 indexed citations
2.
3.
Kurihara, Eisuke, Kazuhiko Shien, Hidejiro Torigoe, et al.. (2019). Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer. Anticancer Research. 39(4). 1767–1775. 8 indexed citations
4.
Torigoe, Hidejiro, et al.. (2019). Growth Process of Metastatic Lung Cancer with a Thin-walled Cavity. Haigan. 59(2). 147–150.
5.
Torigoe, Hidejiro, et al.. (2019). Migration of a hookwire used as a video-assisted thoracoscopic surgery marker into the splenic artery. General Thoracic and Cardiovascular Surgery. 68(2). 194–198. 5 indexed citations
6.
Namba, Kei, Kazuhiko Shien, Yuta Takahashi, et al.. (2018). Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in EGFR -Mutant Non–Small Cell Lung Cancer Cells. Molecular Cancer Research. 17(2). 499–507. 71 indexed citations
7.
Torigoe, Hidejiro, Kazuhiko Shien, Takahiro Yoshioka, et al.. (2018). Therapeutic strategies for afatinib‐resistant lung cancer harboring HER2 alterations. Cancer Science. 109(5). 1493–1502. 20 indexed citations
8.
Sato, Hiroki, Masakiyo Sakaguchi, Hiromasa Yamamoto, et al.. (2018). Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma. Oncogenesis. 7(1). 11–11. 9 indexed citations
9.
Yoshioka, Takahiro, Kazuhiko Shien, Kei Namba, et al.. (2018). Antitumor activity of pan‐HER inhibitors in HER2‐positive gastric cancer. Cancer Science. 109(4). 1166–1176. 35 indexed citations
10.
Sato, Hiroki, Hiromasa Yamamoto, Masakiyo Sakaguchi, et al.. (2018). Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR‐TKIs in non‐small cell lung cancer. Cancer Science. 109(10). 3183–3196. 55 indexed citations
11.
Yamamoto, Hiromasa, Hirotaka Kanzaki, Ken Suzawa, et al.. (2017). Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer. PLoS ONE. 12(2). e0171356–e0171356. 29 indexed citations
12.
Shien, Kazuhiko, Hiroki Sato, Ken Suzawa, et al.. (2017). P3.02b-121 Targeting miR-200c/LIN28B Axis in Acquired EGFR-TKI Resistance Non-Small Cell Lung Cancer Cells Harboring EMT Features. Journal of Thoracic Oncology. 12(1). S1267–S1267. 1 indexed citations
13.
Torigoe, Hidejiro, Junichi Soh, Shuta Tomida, et al.. (2017). Induction chemoradiotherapy using docetaxel and cisplatin with definitive-dose radiation followed by surgery for locally advanced non-small cell lung cancer. Journal of Thoracic Disease. 9(9). 3076–3086. 4 indexed citations
14.
Sato, Hiroki, Kazuhiko Shien, Shuta Tomida, et al.. (2017). Targeting the miR-200c/LIN28B axis in acquired EGFR-TKI resistance non-small cell lung cancer cells harboring EMT features. Scientific Reports. 7(1). 40847–40847. 48 indexed citations
15.
Chen, Haiyang, Kazuhiko Shien, Ken Suzawa, et al.. (2017). Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancer. Oncology Letters. 14(4). 4349–4354. 22 indexed citations
16.
Namba, Kei, Kazuhiko Shien, Takahiro Yoshioka, et al.. (2017). Abstract 3156: Multiple acquired resistance mechanisms against third generation EGFR-TKI osimeritinib in non-smal cell lung cancer cells. Cancer Research. 77(13_Supplement). 3156–3156. 1 indexed citations
17.
Ohtsuka, Tomoaki, Masakiyo Sakaguchi, Hiromasa Yamamoto, et al.. (2016). Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway. Scientific Reports. 6(1). 39557–39557. 22 indexed citations
18.
Yamamoto, Hiromasa, Hirotaka Kanzaki, Ken Suzawa, et al.. (2016). Abstract 4392: Yes1 is the key molecule for the resistance to trastuzumab in breast cancer, and dasatinib overcomes the resistance. Cancer Research. 76(14_Supplement). 4392–4392. 2 indexed citations
19.
Shimoda, Atsushi, Junichi Soh, Hidejiro Torigoe, et al.. (2016). [Cross-sectoral Approach of a Perioperative Management Center for General Thoracic Surgery].. PubMed. 69(1). 20–4. 6 indexed citations
20.
Torigoe, Hidejiro, Shinichi Toyooka, Kuniaki Katsui, et al.. (2016). Induction S-1+Concurrent Radiotherapy Followed by Surgical Resection of Locally Advanced Non-small-cell Lung Cancer in an Elderly Patient.. PubMed. 70(1). 63–5. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jiyeon Yun Breakdown of academic impact, for papers by Matthew R. Strickland Breakdown of academic impact, for papers by Yaning He Breakdown of academic impact, for papers by Trine Lindsted Breakdown of academic impact, for papers by Rebecca Watters Breakdown of academic impact, for papers by Nirit Yarom Breakdown of academic impact, for papers by Shuiping Gao Breakdown of academic impact, for papers by Hoa Q. Trummell Breakdown of academic impact, for papers by Rebecca Pharaon Breakdown of academic impact, for papers by Shinsuke Hashida
Rankless by CCL
2026